Why Insulet (PODD) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zacks Investment Research9/25/2026Positive
PODD
Insulet CorporationNASDAQHEALTHCAREMEDICAL DEVICES
Key Statistics
Market Cap
$9.44B
P/E Ratio
25.59
EPS
$5.32
Beta
1.08
52W High
$354.88
52W Low
$126.40
50-Day MA
$148.87
200-Day MA
$198.24
Dividend Yield
—
Profit Margin
12.30%
Forward P/E
54.95
PEG Ratio
3.31
About Insulet Corporation
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company is headquartered in Acton, Massachusetts.
Fundamentals
| Revenue (TTM) | $3.05B |
| Gross Profit (TTM) | $2.17B |
| EBITDA | $614.90M |
| Operating Margin | 16.20% |
| Return on Equity | 26.00% |
| Return on Assets | 9.72% |
| Revenue/Share (TTM) | $43.62 |
| Book Value | $20.51 |
| Price-to-Book | 15.03 |
| Price-to-Sales (TTM) | 3.09 |
| EV/Revenue | 9.43 |
| EV/EBITDA | 54.64 |
| Quarterly Earnings Growth (YoY) | 328.60% |
| Quarterly Revenue Growth (YoY) | 23.50% |
| Shares Outstanding | $69.35M |
| Float | $69.06M |
| % Insiders | 0.33% |
| % Institutions | 107.11% |
Historical Volatility
HV 10-Day
27.05%
HV 20-Day
30.98%
HV 30-Day
34.73%
HV 60-Day
56.99%
HV Rank
42.1%
Volatility is currently contracting
Analyst Ratings
Consensus ($171.91 target)
4
Strong Buy11
Buy10
HoldLatest News
Insulet Targets Type 2 Retention as Omnipod 6 and Global Growth Gain Momentum
Insulet NASDAQ: PODD Chief Operating Officer Eric Benjamin said the company remains focused on expanding adoption of automated insulin delivery, or AID, systems across large and underpenetrated diabetes markets, while addressing elevated early attrition among certain Type 2 diabetes customers.
MarketBeat9/25/2026Positive
Insulet Corporation (PODD) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum Transcript
Insulet Corporation (PODD) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum Transcript
Seeking Alpha9/24/2026Neutral
Insulet to Participate in Bernstein Insights: Healthcare Leaders and Disruptors – 3rd Annual Healthcare Forum
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will present at Bernstein Insights: Healthcare Leaders and Disruptors – 3rd Annual Healthcare Forum on Thursday, September 24, 2026, at 12:30 p.m. (Eastern Time). The live webcast and replay of the presentation will be accessible on the Insulet Investor Relations website: investors.insulet.com/events. About.
Business Wire9/18/2026Neutral
Insulet Corporation (PODD) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Insulet Corporation (PODD) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Seeking Alpha9/9/2026Neutral
Here's Why Insulet (PODD) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Zacks Investment Research9/9/2026Positive
Is it Prudent to Retain Insulet Stock in Your Portfolio for Now?
PODD's Omnipod 5 adoption, product expansion and raised international growth outlook support its growth prospects despite competitive and cost pressures.
Zacks Investment Research9/8/2026Positive
Insulet (PODD) is a Top-Ranked Value Stock: Should You Buy?
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Zacks Investment Research9/7/2026Positive
Why Is Insulet (PODD) Up 8.1% Since Last Earnings Report?
Insulet (PODD) reported earnings 30 days ago. What's next for the stock?
Zacks Investment Research9/4/2026Positive
Baron SMID Cap ETF Q2 2026 Portfolio Activity
During the quarter, we initiated a position in Advanced Drainage Systems, the leading U.S. manufacturer of stormwater and onsite wastewater management products. We view Axon Enterprise as a market leading "atoms plus electrons" software provider with huge competitive moats. We sold the HeartFlow position in the quarter as we grew incrementally more concerned with the presence of competitors on the market.
Seeking Alpha9/4/2026Neutral
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on PODD and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 9/26/2026